Meningococcal Disease, 2010

Nine cases of Neisseria meningitidis invasive disease (0.2 per 100,000 population) were reported in 2010, compared to 16 cases in 2009. There were 6 serogroup Y cases, 2 serogroup C, and 1 serogroup B. Cases ranged in age from 2 months to 85 years, with a median of 40 years. Seventy-eight percent of the cases occurred in the metropolitan area. Four cases had meningitis, 3 had bacteremia without another focus of infection, 1 had pneumonia, and 1 had tracheobronchitis. One death occurred in a case less than 1 year of age with bacteremia attributed to serogroup C.

In 2010, a new meningococcal conjugate vaccine (Menveo) was licensed for use in the United States for 11-55 year-olds and has demonstrated non-inferiority to MCV4 (Menactra). Menactra was licensed for use in the United States in January 2005 for persons aged 11 to 55 years, and was the first meningococcal polysaccharide-protein conjugate vaccine for serogroups A,C,Y, and W-135 (MCV4). In 2007, the license was approved to include 2-10 year olds. The Advisory Committee on Immunization Practices and American Academy of Pediatrics recommend immunization with either vaccine routinely at age 11-12 years or at high school entry and a booster dose at age 16, as well as for college freshmen living in dormitories, and other groups in the licensed age range previously determined to be at high risk. In 2006, MDH in collaboration with the CDC and other sites nationwide, began a case-control study to examine the efficacy of MCV4. In 2010, 1 case occurred among 11-22 year olds. The case had serogroup Y disease, was not vaccinated, and was not in school. The case was eligible for the MCV4 study.

  • For up to date information see>> Meningococcal Disease
  • [an error occurred while processing this directive]

Updated Monday, 28-Nov-2011 14:10:34 CST